Fresh from Pfizer deal, Roivant posts 'best-in-class' ulcerative colitis data on rival to Prometheus prospect

Roivant Sciences has shown its hand in the red-hot race for a new ulcerative colitis market. Weeks after Prometheus Biosciences wowed investors, and with the ink on its deal with Pfizer to enter the race still drying, Roivant has shared phase 2b data it claims position it as a best-in-class contender.